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ABSTRACT
Objective Currently effective symptom- based screening 
of patients suspected of COVID-19 is limited. We aimed 
to investigate age- related differences in symptom 
presentations of patients tested positive and negative for 
SARS- CoV-2.
Design
Setting Calls to the medical helpline (1-8-1-3) and 
emergency number (1-1-2) in Copenhagen, Denmark. At 
both medical services all calls are recorded.
Participants We included calls for patients who called 
for help/guidance at the medical helpline or emergency 
number prior to receiving a test for SARS- CoV-2 between 
April 1st and 20th 2020 (8423 patients). Among these calls, 
we randomly sampled recorded calls from 350 patients 
who later tested positive and 250 patients tested negative 
and registered symptoms described in the call.
Outcome
Results After exclusions, 544 calls (312 SARS- CoV-2 
positive and 232 negative) were included in the analysis. 
Fever and cough remained the two most common 
of COVID-19 symptoms across all age groups and 
approximately 42% of SARS- CoV-2 positive and 20% of 
negative presented with both fever and cough. Symptoms 
including nasal congestion, irritation/pain in throat, 
muscle/joint pain, loss of taste and smell, and headache 
were common symptoms of COVID-19 for patients younger 
than 60 years; whereas loss of appetite and feeling unwell 
were more commonly seen among patients over 60 years. 
Headache and loss of taste and smell were rare symptoms 
of COVID-19 among patients over 60 years.
Conclusion Our study identified age- related differences 
in symptom presentations of SARS- CoV-2- positive patients 
calling for help or medical advice. The specific symptoms 
of loss of smell or taste almost exclusively reported by 
patients younger than 60 years. Differences in symptom 
presentation across age groups must be considered when 
screening for COVID-19.
INTRODUCTION
COVID-19 has been classified as a pandemic 
since 11 March 2020. Politicians world-
wide have initiated serious actions in order 
to hinder spread of the disease and retain 
sufficient healthcare capacity.1 Countries 
have increased demand for testing and 
protection equipment, which currently is 
exceeding production capacity.2 The scarce 
access to resources results in an urgent need 
to prioritise patients sent to the emergency 
departments and testing facilities.2 Effective 
symptom- based screening for COVID-19 is 
difficult: common influenza- like symptoms of 
fever, cough and fatigue have been reported 
by patients with COVID-193–5; however, these 
symptoms are experienced by up to 20% 
of a population during a winter season.6 
Other symptoms have been found to include 
myalgia, headache, sore throat, runny nose, 
Strengths and limitations of this study
 ► This is the first study reporting symptoms of 
COVID-19 as they are presented in medical tele-
phone consultations.
 ► We investigated the presence of 36 symptoms 
and reported variations in symptom presentations 
across age groups.
 ► By randomly sampling calls to this study from 
SARS- CoV-2- tested individuals calling the 24- hour 
medical helpline and emergency medical services, 
our study included patients from all ages with high 
generalisability to the general population.
 ► Information of patient characteristics, including co-
morbidities, socioeconomic factors, ethnicity and 
living condition, could have improved the analysis.
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diarrhoea, shortness of breath, nausea, vomiting, and loss 
of smell and taste.3–5 7
As countries worldwide rolled out full or partial soci-
etal lockdown, people were encouraged mostly to call 
local healthcare services rather than physical visits, and 
telephone and video consultations have in many places 
replaced the physical encounter with patients placing 
new demands of not only which symptoms are predictive 
of COVID-19 but also knowledge of how symptoms are 
communicated.
Although some studies have investigated the symptoms 
of COVID-19, little attention has been devoted to investi-
gating symptoms as they are described by patients or their 
relatives/caregivers in telephone consultations. Addition-
ally, it remains unclear whether the described symptoms 
are common among both young and elderly patients, as 
none of the previously mentioned studies have reported 
symptoms according to age groups. In order to improve 
healthcare professionals’ possibilities to screen patients 
for COVID-19 in telephone consultations, we need to 
improve knowledge of how patients across ages present 
their symptoms. We aimed to describe differences in 
symptom presentation across age groups of patients 
calling for medical advice or help prior to receiving a test 
for SARS- CoV-2.
METHODS
To investigate the symptom presentation of SARS- CoV-
2- positive and negative patients, we have systematically 
listened and recorded symptoms described by patients 
calling for help and guidance at the 24- hour medical 
helpline (1813- medical helpline) and 1-1-2 emergency 
number (equivalent to 9-1-1) in Copenhagen, Denmark, 
prior to a SARS- CoV-2 swab test. The study is conducted 
as a nested case–control in accordance with the STrength-
ening the Reporting of OBservational studies in Epidemi-
ology statement.
Setting
In Denmark, the healthcare system is public and tax- 
funded, and most medical services including calling for 
medical help/advice, hospital treatment and SARS- CoV-2 
testing are free of charge. Between 1 April and 20 April, 
symptomatic patients were eligible for testing and could 
get directly referred by either contacting their general 
practitioner or by calling the regional 24- hour medical 
helpline (1813- medical helpline). Additionally, patients 
either hospitalised or undergoing surgery were tested if 
they were symptomatic. In the Capital Region, Denmark, 
inhabitants should, and most often do, contact the 1813- 
medical helpline, 1-1-2 emergency number or a general 
practitioner to get referred to an emergency depart-
ment.8 The 1813- medical helpline and the 1-1-2 emer-
gency number is a combined medical service co- located 
at one facility, the Copenhagen Emergency Medical 
Service (EMS), serving 1.8 million citizens.8 Citizens 
with non- urgent medical conditions should contact their 
general practitioner during opening hours on working 
days or dial 1-8-1-3 to reach the 24- hour medical help-
line, where healthcare professionals including nurses 
and doctors provide medical guidance, refer to emer-
gency departments and dispatch ambulances if neces-
sary. In case of an emergency, citizens should call the 
emergency number 1-1-2. Due to extraordinary workload 
caused by COVID-19, the 1813- medical helpline opened a 
COVID-19 hotline. When dialling 1-8-1-3, patients calling 
regarding COVID-19 were referred to the COVID-19 
hotline, whereas patients calling regarding other matters 
remained in queue for the 1813- medical helpline. Both 
patients calling the COVID-19 hotline and directly to the 
1813- medical helpline could be referred to testing.
All symptoms indicative of infection could result in 
referral to a SARS- CoV-2 test. These symptoms included 
fever, cough, breathing difficulties, sore throat, headache 
and muscle pain, but was not limited to these as health 
professionals at the 1813- medical helpline, COVID-19 
hotline, general practice and hospitals should assess the 
patient and refer to test accordingly. At the COVID-19 
hotline and 1813- medical helpline, patients were typically 
questioned about age, comorbidity, respiratory distress, 
fever, cough, headache, muscle pain and diarrhoea.9
All calls to the Copenhagen EMS (1813- medical help-
line, COVID-19 hotline and 1-1-2 emergency number) 
are recorded and stored, together with patient informa-
tion including age, sex, a medical report and the patients’ 
civil registration number (a unique number assigned to 
all Danish residents).10 11
SARS-CoV-2 test
In Denmark, patients suspected of COVID-19 were tested 
using a PCR test for SARS- CoV-2 with nasopharyngeal 
swab. Test results were identified from the patient’s 
electronic medical journal and were linked to previous 
calls to the Copenhagen EMS using the civil registration 
number. The majority of tests for SARS- CoV-2 have been 
carried out at hospitals and a minority at the general prac-
titioners, for this article only hospital tests are included.
Symptom presentation
All researchers collected data on symptoms by listening 
to calls and recording information in a survey guide. The 
survey guide included questions on the identity of the 
caller, purpose of the call, symptoms, and possible risk 
behaviour including recent travel and contact with SARS- 
CoV-2- positive individuals. Tic boxes were used to confirm 
presence of specific symptoms and a text box was added 
to allow for description of possible novel symptoms. The 
original survey in Danish and an English translation are 
available in the online supplemental material 1.
The survey was developed and tested in two rounds 
prior to the data collection. All researchers listened to the 
same 10 randomly selected test calls in each round. We 
evaluated inter- rater variability using free- marginal multi-
rater kappa for each test round.12 The average kappa 
value was estimated to be higher than 0.8 in both tests.
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Population
Between 1 April and 20 April 2020, we identified all calls to 
the 1813- medical helpline and 1-1-2 emergency number 
for individuals tested for SARS- CoV-2 up to 48 hours after 
the call resulting in 14 401 calls from 8423 patients.
After exclusion of inconclusive test results, we identi-
fied the last call for each patient and randomly sampled 
600 patients (350 tested SARS- CoV-2 positive and 250 
negative). This would provide the study with a power 
of 90% to detect differences in symptom prevalence of 
10% between the two groups with a 5% significance level 
and an enrolment rate of 1.5. Calls regarding following 
matters were excluded: (1) calls not concerning the 
patient’s condition, for example, patients calling to ask 
about test results or concerning previously requested 
transports; (2) calls regarding childbirth, assaults, traffic 
Figure 1 Flow chart describing the selection of calls for SARS- CoV-2- positive and negative patients. C=number of calls; 
P=number of people.
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accidents or similar obviously not related to COVID-19. 
Such calls might appear in the random sample as patients 
who had or developed symptoms during hospitalisa-
tion were tested to minimise in- hospital transmission of 
COVID-19.
Analysis
Data were collected using Research Electronic Data 
Capture, which is a secure, web- based software plat-
form designed to support data capture for research 
studies.13 14 Prior to analysis, symptoms described in the 
free text option were classified into one of the pre- existing 
categories when possible.
The proportion of SARS- CoV-2 positive and negative 
that presented with each symptom was estimated. P values 
with 5% significance level were estimated using F- test for 
continuous variables and Fisher’s exact test for categor-
ical variables. The proportion of SARS- CoV-2 positive 
and negative presenting with each symptom was also esti-
mated in three age groups (0–35, 36–60 and >60 years) 
and in five age groups for sensitivity analysis (0–17, 18-35, 
36–50, 51–70 and >70 years). Venn diagrams were used 
to illustrate the prevalence of combinations of the three 
most common symptoms in three age groups.
Patients could receive a SARS- CoV-2 test performed 
by being either referred to a test centre or admitted to 
a hospital. Therefore, we have possibly included patients 
calling the Copenhagen EMS for conditions unrelated to 
COVID-19, for example, cardiovascular disease, who were 
subsequently tested for SARS- CoV-2 to minimise risk of 
in- hospital spread. We expected that these patients were 
less likely to have COVID-19 and more likely to present 
with chest pain and trauma. To assess whether this biased 
our results, we investigated the prevalence of the symp-
toms in the subset of patients suspected of COVID-19 
by the healthcare personnel at the Copenhagen EMS, 
defined as calls where a note of COVID-19 were added to 
the electronic medical report at the Copenhagen EMS, as 
we expect that these patients were tested due to suspicion 
of COVID-19.
Data management and analysis of data were carried out 
in R version 3.6.1.15
RESULTS
From 1 April to 20 April 2020, we identified 14 401 calls to 
the 1-1-2 emergency number and 1813- medical helpline 
from people tested for SARS- CoV-2 within 48 hours of the 
call. Inconclusive test results were excluded (47 calls from 
31 individuals) and only the last call prior to a test was 
kept resulting in 8414 calls (662 SARS- CoV-2 positive and 
7752 negative) (see flow chart in figure 1). We randomly 
sampled calls from 350 SARS- CoV-2 positive and 250 
negative and recorded their symptoms. After exclusion 
of 56 calls (38 SARS- CoV-2 positive and 18 SARS- CoV-2 
negative), 312 calls from SARS- CoV-2- positive and 232 
calls from SARS- CoV-2- negative patients were included 
for analysis (figure 1).
Patients tested positive for SARS- CoV-2 were on average 
older compared with those tested negative (mean age 51 
vs 43), and more often men (48.4% vs 40.1%) (table 1). 
Among patients tested SARS- CoV-2 positive, 32.1% had 
been in contact with an infected individual. This was only 
true for 8.2% of those tested negative (table 1).
In table 2 the symptoms are presented stratified by 
SARS- CoV-2 positive and negative. Among the SARS- CoV-2 
positive, the most common symptoms were fever (64.4%), 
cough (63.5%), breathing problems (38.8%) followed by 
headache (34%). The most common symptoms of the 
SARS- CoV-2 negative were cough (49.1%), fever (44.8%), 
breathing problems (44%) and irritation/pain in the 
throat (40.1%). Loss of smell and taste was found to be 
almost exclusively a symptom among the SARS- CoV-2 
positive. Chest pain and irritation/pain in the throat were 
more common among the SARS- CoV-2 negative than the 
Table 1 Characteristics of patients tested SARS- CoV-2 positive and negative
SARS- CoV-2 positive SARS- CoV-2 negative P value
  312 232
Contact with SARS- CoV-2 positive* 100 (32.1) 19 (8.2) <0.001
Travelled abroad within the last month 6 (1.9) 3 (1.3) 0.739
Sex (male) 151 (48.4) 93 (40.1) 0.056
Age mean (SD) 51 (22.42) 43 (24.04) <0.001
Age groups 0.014
  Under 36 89 (28.5) 89 (38.4)
  36–60 116 (37.2) 87 (37.5)
  Over 60 107 (34.3) 56 (24.1)
Non- emergency calls (1813- medical helpline) 292 (93.6) 212 (91.4) 0.407
N=544.
*All patients tested positive for SARS- CoV-2 were advised to quarantine until 48 hours after end of symptoms. Patients can infect others with 
SARS- CoV-2 days before developing symptoms themselves while they are still unaware of their infection.19
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positive but neither symptoms were specific for SARS- 
CoV-2- negative individuals.
In figure 2 the symptom presentation of SARS- CoV-
2- positive and negative patients is shown by age groups 
(under 36, 36–60 and over 60 years). Among the SARS- 
CoV-2- positive patients younger than 36 years, 36% 
presented with nasal congestion, which was twice as 
common as among the negative (18%). Presenting with 
headache was also common for patients younger than 60 
years (28%–34% of the negative and 43%–46% of the 
positive), but less common among the patients older than 
60 years (9% of the negative and 14% of the positive). 
Similarly, the proportion of both SARS- CoV-2 positive 
and negative presenting with irritation/pain in the throat 
decreased with increasing age. Loss of smell and taste 
was predominantly found among younger SARS- CoV-2- 
positive patients, where 16% had loss of smell and 16% 
had loss of taste.
Table 2 Symptoms of patients tested SARS- CoV-2 positive and negative
SARS- CoV-2 positive SARS- CoV-2 negative P value
N (%) 312 232
Fever 201 (64.4) 104 (44.8) <0.001
Cough 198 (63.5) 114 (49.1) 0.001
Breathing problems 121 (38.8) 102 (44.0) 0.252
Headache 106 (34.0) 59 (25.4) 0.038
Unwell 91 (29.2) 52 (22.4) 0.094
Fatigue 81 (26.0) 46 (19.8) 0.102
Irritation/pain in throat 78 (25.0) 93 (40.1) <0.001
Muscle/joint pain 74 (23.7) 29 (12.5) 0.001
Nasal congestion 66 (21.2) 35 (15.1) 0.075
Loss of taste 34 (10.9) 2 (0.9) <0.001
Chest pain 32 (10.3) 43 (18.5) 0.008
Loss of smell 30 (9.6) 1 (0.4) <0.001
Dizzy 27 (8.7) 22 (9.5) 0.764
Lung/breathing- related pain 26 (8.3) 30 (12.9) 0.088
Pain in back 25 (8.0) 17 (7.3) 0.871
Cold/clammy 25 (8.0) 14 (6.0) 0.406
Loss of appetite 25 (8.0) 12 (5.2) 0.229
Diarrhoea 22 (7.1) 13 (5.6) 0.597
Abdominal pain 13 (4.2) 20 (8.6) 0.044
Nausea 13 (4.2) 14 (6.0) 0.327
Pain in extremities 13 (4.2) 13 (5.6) 0.543
Confused 12 (3.8) 11 (4.7) 0.669
Pale 12 (3.8) 4 (1.7) 0.201
Vomit 10 (3.2) 15 (6.5) 0.096
Anxiety 10 (3.2) 14 (6.0) 0.140
Skin 9 (2.9) 5 (2.2) 0.786
Palpitations 8 (2.6) 7 (3.0) 0.795
Falls 7 (2.2) 8 (3.4) 0.435
Pain in/around eyes/ears 5 (1.6) 5 (2.2) 0.751
Pain in neck shoulder 4 (1.3) 8 (3.4) 0.137
Unconscious 3 (1.0) 4 (1.7) 0.467
Impaired vision/hearing 3 (1.0) 0 (0.0) 0.265
Oedema 2 (0.6) 4 (1.7) 0.409
Impaired movement 2 (0.6) 2 (0.9) 1.000
Cramps 1 (0.3) 5 (2.2) 0.088
N=544.
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Patients older than 60 years more often presented with 
loss of appetite (17% of the SARS- CoV-2 positive and 7% 
of the negative). Feeling unwell was also common among 
the patients over 60 years, especially the SARS- CoV-2 posi-
tive (38% of the SARS- CoV-2 positive vs 20% of the nega-
tive) (figure 2).
In figure 3 the proportion of patients presenting with 
one or more of the three most common symptoms of that 
age group is shown for SARS- CoV-2 positive and negative. 
Presenting with both cough and fever was more common 
among the SARS- CoV-2 positive (overall: 42%, under 36: 
40%, 36–60: 47% and over 60: 38%) compared with those 
tested SARS- CoV-2 negative (overall: 20%, under 36: 17%, 
36–60: 28% and over 60: 14%). Among patients above age 
60 years, 33% of the SARS- CoV-2 positive presented with 
breathing problems and fever and 19% with breathing 
problems, fever and cough. This symptom combination 
was less common among SARS- CoV-2- negative patients 
over 60 years (12% with fever and breathing problems 
and 5% with breathing problems, fever and cough) 
(figure 3).
Sensitivity analysis
We investigated the symptom presentation of patients 
suspected of COVID-19 by the healthcare professionals 
at the Copenhagen EMS (see online supplemental table 
1). In the subpopulation, the most common symptoms 
of the SARS- CoV-2 positive and negative were similar to 
those found in the total population (SARS- CoV-2 posi-
tive: cough (69.6%), fever (69%) and headache (38.6%); 
SARS- CoV-2 negative: cough (60.5%), irritation/pain 
in throat (52.4%) and fever (49.2%)), although cough 
was more common among SARS- CoV-2 negative in the 
subpopulation. The proportion of patients with chest 
pain was not found to differ between the SARS- CoV-2 
positive and negative in this analysis. Loss of smell and 
taste remained specific among the positive, and similarly 
Figure 2 Symptom presentation of SARS- CoV-2 positive and negative by age groups. The figure illustrates the percentage 
of SARS- CoV-2 positive and negative patients that presented each of the listed symptoms by age groups. Only symptoms 
experienced by more than 30 patients in total the population (N=544) were included.
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irritation/pain in the throat remained more common 
among the negative.
Additionally, we investigated the symptom presentation 
of the SARS- CoV-2- tested patients across five age groups. 
Overall, similar patterns were identified when stratifying 
across five age groups as when stratifying across three age 
groups (see online supplemental figure 1).
DISCUSSION
The main finding from this study was that loss of smell 
and loss of taste were identified as important specific 
symptoms of COVID-19. The symptom presentations 
varied across age groups, where symptoms including nasal 
congestion, muscle/joint pain, loss of taste and smell 
and headache were common symptoms of COVID-19 for 
patients younger than 60 years; while loss of appetite and 
feeling unwell were more common among patients over 
60 years.
We found that 10.9% of SARS- CoV-2 positive had loss of 
taste and 9.6% had loss of smell. Previous studies found 
that among SARS- CoV-2- positive patients—65% in a 
British population, 67% in a US population and 64% of 
an Italian population—reported loss of smell or taste.3 4 
However, only 2%–11% of SARS- CoV-2- positive individ-
uals in the Icelandic population reported these symp-
toms.5 It is uncertain why these estimates vary so widely, 
but one suggestion is that media coverage of the novel 
symptoms might have influenced people’s perception of 
their symptoms.4 16 Additionally, the selection of patients 
differed between the studies. Ours and the Icelandic 
study5 included a broad population, including small chil-
dren and the elderly, who might not be able to report 
specific symptoms of smell and taste. Finally, patients 
were not systematically asked about alterations of smell 
and taste in our study. It is therefore possible that symp-
toms were present but just not presented.
Figure 3 Combinations of the three most common symptoms for each age group by SARS- CoV-2 positive and negative. 
The percentage represents the prevalence of the given symptom or symptom combination in each subgroup. The area of 
the bubbles increases with increasing per cent. Overlapping areas indicate a combination of two or three symptoms, and 
the percentage is the proportion of patients in this subgroup who had this symptom combination. The three most common 
symptoms were identified for each age group regardless of SARS- CoV-2 test result. For individuals under 36 years, this was 
cough, fever and irritation/pain in throat; for individuals aged 36–60 and over 60 years, this was fever, cough and breathing 
problems. N=544 (232 negative and 312 positive).
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Another important finding was that among SARS- CoV-2 
positive, 32% had been in contact with another SARS- CoV-2 
infected, which was true for only 8% of SARS- CoV-2 nega-
tive. This makes the question about known contact with a 
SARS- CoV-2- positive person a key priority in screening of 
COVID-19 and further in referral to SARS- CoV-2 testing.
Although symptoms including chest pain and irri-
tation/pain in throat were found to be more common 
among SARS- CoV-2 negative, these symptoms were also 
relatively common among the positive. Neither of these 
symptoms can therefore rule out SARS- CoV-2 infection.
Strengths and limitations
A strength of this study is the stratification of symptoms on 
age providing important knowledge of age- related differ-
ences in symptom presentation of COVID-19. However, 
we still lack knowledge about whether COVID-19 presents 
differently depending on other conditions as the occur-
rence of chronic diseases. Likewise, the timing of calls 
over the course of illness can vary and reflect the pres-
ence of symptoms.
We assessed bias caused by inclusion of calls unre-
lated to COVID-19 in a sensitivity analysis including only 
calls where the healthcare professional had suspected 
COVID-19. This analysis showed similar findings as the 
main analysis, although the proportion of chest pain 
among the SARS- CoV-2 negative was smaller in the sensi-
tivity analysis, indicating that some patients with cardiac 
conditions might have been included in the study popu-
lation, although they were supposedly only tested due to 
hospitalisation.
A total of 27% (662 of 2456) of all SARS- CoV-2 
positive in the capital region between 1 April and 
20 April 202017 18 were identified among calls to the 
Copenhagen EMS. This study included 12.7% (312 of 
2456) of SARS- CoV-2 positive in the region during the 
period and 47% (312 of 662) of those in contact with 
the Copenhagen EMS. The remaining SARS- CoV-2 
positive cases are assumed to be symptomatic health-
care professionals, who could get referred through 
their employment, symptomatic citizens referred by 
general practitioners and hospital- admitted patients 
developing symptoms during admission. Regardless of 
the type of referral, the symptomatic criteria for being 
referred to test were the same, also for healthcare 
professionals. We therefore assume that our results are 
largely generalisable to the general Danish population.
Implications
Though symptoms of fever and cough remain common 
across age groups, other symptoms including loss of 
smell and taste, headache, nasal congestion and loss of 
appetite were found to be more age specific. To improve 
telephone- based screening for COVID-19, differences 
in symptom presentation across age groups must be 
considered.
Our findings also emphasised that symptomatic 
patients, who are aware of possible infection by contact to 
a SARS- CoV-2- positive individual, must be tested, as these 
patients are at higher risk of being SARS- CoV-2 positive 
themselves.
CONCLUSION
Our study indicates that there are important age- related 
differences in the symptoms reported by SARS- CoV-2- 
positive patients calling for help or advice at the medical 
helpline and 1-1-2 emergency number. Loss of smell or 
taste was found to be indicative of COVID-19, but these 
symptoms were almost exclusively reported by patients 
younger than 60 years. Differences in symptom presenta-
tion across age groups must be considered in telephone- 
based screening for COVID-19.
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